3-乙基-2-苯并咪唑酮 | 10045-45-1

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 3-乙基-2-苯并咪唑酮
• 中文别名: 氯唑沙宗类似物
• 英文名称: N-ethylbenzimidazolinone
• 英文别名: 1-ethyl-2-benzimidazolinone；1-EBIO；1-ethyl-1,3-dihydrobenzoimidazol-2-one；EBIO；1-ethyl-1,3-dihydro-2H-benzimidazol-2-one；3-ethyl-1H-benzimidazol-2-one
• CAS: 10045-45-1
• 化学式: C₉H₁₀N₂O
• mdl: MFCD00005715
• 分子量: 162.191
• InChiKey: CXUCKELNYMZTRT-UHFFFAOYSA-N

物化性质

• 熔点：
  118-120 °C(Solv: ethyl acetate (141-78-6))
• 密度：
  1.161±0.06 g/cm3(Predicted)
• 溶解度：
  二甲基亚砜：≥20mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 安全说明：
  S26
• 危险类别码：
  R22,R36
• WGK Germany：
  3
• 危险品运输编号：
  NONH for all modes of transport
• 海关编码：
  2933990090
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H302,H319
• 储存条件：
  存储于室温下

SDS

Name:	1-Ethyl-2-benzimidazolinone 98% Material Safety Data Sheet
Synonym:
CAS:	10045-45-1

Section 1 - Chemical Product MSDS Name:1-Ethyl-2-benzimidazolinone 98% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
10045-45-1	1-ethyl-2-benzimidazolinone, 98%	98	233-148-1

Hazard Symbols: Not available.
Risk Phrases:

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
The toxicological properties of this material have not been investigated. Use appropriate procedures to prevent opportunities for direct contact with the skin or eyes and to prevent inhalation.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower lids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of soap and water for at least 15 minutes while removing contaminated clothing and shoes.
Remove contaminated clothing and shoes.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire.
Autoignition Temperature: Not available.
Flash Point: Not available.
NFPA Rating: Not published.
Explosion Limits, Lower: Not available.
Upper: Not available.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Avoid contact with eyes, skin, and clothing. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Keep container closed when not in use.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use process enclosure, local exhaust ventilation, or other engineering controls to control airborne levels.
Personal Protective Equipment Eyes: Wear chemical goggles.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to minimize contact with skin.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements must be followed whenever workplace conditions warrant a respirator's use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Not available.
Appearance: beige to brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Vapor Density: Not available.
Evaporation Rate: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 120.00 - 126.00 deg C
Decomposition Temperature: Not available.
Solubility: Not available.
Specific Gravity/Density: Not available.
Molecular Formula: C9H10N2O
Molecular Weight: 162.19

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, strong oxidants.
Incompatibilities with Other Materials:
Not available.
Hazardous Decomposition Products:
Irritating and toxic fumes and gases.
Hazardous Polymerization: Not available.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 10045-45-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-ethyl-2-benzimidazolinone, 98% - Not listed by ACGIH, IARC, NIOSH, NTP, or OSHA.
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION
For further information, contact Fisher Scientific.

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

CDG/CPL
IMO
Not regulated as a hazardous material.
IATA
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.
Canadian TDG
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 10045-45-1:
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
WHMIS: Not available.
CAS# 10045-45-1 is not listed on Canada's Ingredient Disclosure List.
Exposure Limits
US FEDERAL
TSCA
CAS# 10045-45-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

EBIO是一种钙敏感性钾通道的激活剂，常用于探究K+通道在各种生理功能中的作用。

反应信息

• 作为反应物：
  描述：

  3-乙基-2-苯并咪唑酮 在 三氯氧磷 作用下， 反应 4.0h， 生成 (9ci)-2-氯-1-乙基-1H-苯并咪唑
  参考文献：
  名称：

  Triazolines. Part 32. Synthesis of 1-alkyl-2-aminobenzimidazoles from 5-amino-1-(2-nitroaryl)-1,2,3-triazolines

  摘要：

  5-Amino-l-(2-nitroaryl)-1,2,3-triazolines 5 are converted into 1-alkyl-2-aminobenzimidazoles 7 in refluxing triethyl phosphite. The reaction occurs via thermal rearrangement of 5 followed by nitrogen elimination which produces N2-(2-nitroaryl)amidines 8 as intermediates. Reduction of the nitro group to nitrene, addition to the C=N bond and rearrangement of the intermediate 2,2-disubstituted benzimidazoles accounts for the formation of the end products.

  DOI：

  10.1039/p19920002709
• 作为产物：
  描述：

  1-N-乙基苯-1,2-二胺 在 盐酸 作用下， 生成 3-乙基-2-苯并咪唑酮
  参考文献：
  名称：

  Synthesis of Some Substituted Benzoxazolones

  摘要：

  DOI：

  10.1021/ja01540a038

文献信息

• [EN] PARG INHIBITORY COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE PARG
  申请人：CANCER REC TECH LTD

  公开号：WO2016097749A1

  公开（公告）日：2016-06-23

  The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity: wherein R1a, R1b, R1c, R1d, R1e, W, X1, X2, X3, X4, X5, X6, X7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated.

  本发明涉及作为PARG（Poly ADP-ribose glycohydrolase）酶活性抑制剂的化合物I的公式，其中R1a、R1b、R1c、R1d、R1e、W、X1、X2、X3、X4、X5、X6、X7、c分别如本文所定义。本发明还涉及制备这些化合物的方法，包括含有它们的药物组合物，以及它们在治疗增殖性疾病（如癌症）以及其他涉及PARG活性的疾病或症状中的用途。
• Photocatalytic Intramolecular C–H Amination Using <i>N</i>-Oxyureas as Nitrene Precursors
  作者：Ryan A. Ivanovich、Dilan E. Polat、André M. Beauchemin

  DOI：10.1021/acs.orglett.0c02200

  日期：2020.8.21

  Nitrenes are remarkable high-energy chemical species that enable direct C–N bond formation, typically via controlled reactions of metal-stabilized nitrenes. Here, in contrast, the combined use of photocatalysis with careful engineering of the precursor enabled C–H amination forming imidazolidinones and related nitrogen heterocycles from readily accessible hydroxylamine precursors. Preliminary mechanistic

  硝基是非凡的高能化学物质，通常可通过金属稳定的腈的受控反应直接形成C-N键。相比之下，光催化与前体的精心设计相结合，可以使C–H胺化反应从易得的羟胺前体形成咪唑烷酮和相关的氮杂环。初步的机理结果与游离氨基甲酰基三重态氮烯作为反应性中间体的形成是一致的。
• Highly Efficient Synthesis of Ureas and Carbamates from Amides by Iodosylbenzene-Induced Hofmann Rearrangement
  作者：Peng Liu、Zhiming Wang、Xianming Hu

  DOI：10.1002/ejoc.201101784

  日期：2012.4

  A simple and efficient method for the synthesis of 1,3-disubstituted ureas and carbamates from amides by using iodosylbenzene as the oxidant is described. Symmetric and asymmetric ureas and carbamates can be prepared by this procedure in up to 98 % yield. Ureidopeptides can also be prepared in good yield by this method.

  描述了一种使用碘代苯作为氧化剂从酰胺合成 1,3-二取代脲和氨基甲酸酯的简单有效的方法。对称和不对称尿素和氨基甲酸酯可以通过该程序以高达 98% 的产率制备。通过该方法也可以以良好的产率制备脲肽。
• Phenylaminopropanol derivatives and methods of their use
  申请人：Kim Younghee Callain

  公开号：US20050222148A1

  公开（公告）日：2005-10-06

  The present invention is directed to phenylaminopropanol derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

  本发明涉及式I的苯胺丙醇衍生物： 或其药学上可接受的盐，含有这些衍生物的组合物，以及它们用于通过单胺再摄取改善的症状的预防和治疗方法，包括但不限于血管运动症状（VMS）、性功能障碍、胃肠道和泌尿系统疾病、慢性疲劳综合征、纤维肌痛综合征、神经系统疾病，以及其中的组合，特别是从包括重性抑郁障碍、血管运动症状、压力性和切勿性尿失禁、纤维肌痛、疼痛、糖尿病性神经病变以及其中的组合的一组中选择的那些症状。
• Ramoplanin derivatives possessing antibacterial activity
  申请人：Raju G. Bore

  公开号：US20060211603A1

  公开（公告）日：2006-09-21

  Novel ramoplanin derivatives are disclosed. These ramoplanin derivatives exhibit antibacterial activity. As the compounds of the subject invention exhibit potent activities against gram positive bacteria, they are useful antimicrobial agents. Methods of synthesis and of use of the compounds are also disclosed.

  新型拉莫普兰衍生物已被披露。这些拉莫普兰衍生物表现出抗菌活性。由于本发明的化合物对革兰氏阳性细菌表现出强效活性，它们是有用的抗微生物药剂。该化合物的合成方法和使用方法也已被披露。

表征谱图